Received: 7 December 2018
Accepted: 10 January 2019
First Online: 28 January 2019
Ethics approval and consent to participate
: This survey was ethics reviewed and approved by Advarra (formerly Institutional Review Board Services; reference # Pro00018492), and the University of Victoria subsequently approved a post-survey sub-analysis of the substitution data (reference # 17-188). A password-protected link to an online survey available in French and English was sent out to 16,675 Tilray patients in January 2017. Clicking on the link in the email invitation took patients to the IRB approved Informed Consent Form (ICF), and consent was gathered electronically.
: Not applicable.
: This research was supported by Tilray, a federally authorized Canadian medical cannabis production and research company. PL is Global Vice-President, Patient Research and Access for Tilray (ExternalRef removed), and he designed the survey. Formal analysis was conducted by EB, who has no conflict to disclose. Preliminary data analysis was conducted by NJ, Senior Science Advisor, Data & Analytics, at Leafly, an online cannabis website.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.